Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Ischemic stroke: cumulative recurrence rates
- Reducing recurrent stroke risk: lifestyle changes
- Secondary prevention
- Platelet antiaggregants
- Aspirin for TIA and stroke
- Clopidogrel - CAPRIE trial
- CAPRIE trial: primary analysis
- CAPRIE trial: outcome by disease strata
- MATCH trial: study design
- MATCH trial: results
- CHARISMA trial
- CHARISMA trial: results
- Aspirin-sustained release dipyridamole (ESPS-2)
- ESPRIT trial
- ESPRIT trial: results
- Secondary prevention: anticoagulants
- Atrial fibrillation: warfarin vs. antiplatelet drugs
- Atrial fibrillation: stroke risk stratification
- Warfarin aspirin recurrent stroke study (WARSS)
- WARSS trial: results
- WASID trial
- WASID trial: results
- Secondary prevention: blood pressure
- Antihypertensives- secondary prevention (UK-TIA)
- BP treatment and stroke risk
- PROGRESS trial
- PROGRESS trial: results
- Secondary prevention: lipid lowering
- Statins for prevention of CVD and stroke
- Heart protection study
- HPS results: patients with vs. without prior stroke
- SPARCL: study design
- SPARCL results: primary endpoint
- SPARCL results: secondary endpoints
- SPARCL: NNT to prevent one event over 5 years
- Safety
- Post-hoc analyses: cerebrovascular endpoints
- Post-hoc analysis: ischemic \ hemorrhagic stroke
- Multivariable Cox regression model (1)
- Multivariable Cox regression model (2)
- Outcome by entry event: fatal or non-fatal stroke
- Summary
Topics Covered
- Risk of recurrent stroke
- Lifestyle modification
- Platelet antiaggregant therapy; aspirin, clopidogrel, aspirin plus sustained-release dypiridamole
- Antihypertensive therapy
- Lipid lowering therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Goldstein, L. (2008, October 27). Medical therapy for secondary prevention of ischemic stroke [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 5, 2024, from https://doi.org/10.69645/WJPO8900.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Larry Goldstein has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.